These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24619589)

  • 21. Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa).
    Franchini M; Mannucci PM
    Expert Opin Drug Saf; 2017 Mar; 16(3):405-410. PubMed ID: 28103444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII.
    Toschi V
    Curr Opin Mol Ther; 2010 Oct; 12(5):617-25. PubMed ID: 20886394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report.
    Takeyama M; Nogami K; Kobayashi R; Ogiwara K; Taniguchi A; Nakanishi Y; Inagaki Y; Tanaka Y; Shima M
    Int J Hematol; 2018 Aug; 108(2):199-202. PubMed ID: 29383626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIII.
    Konigs C; von Hentig N
    Drugs Today (Barc); 2009 Jul; 45(7):549-61. PubMed ID: 19834631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant factor VIII: past, present and future of treatment of hemophilia A.
    Raso S; Hermans C
    Drugs Today (Barc); 2018 Apr; 54(4):269-281. PubMed ID: 29869648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications.
    Hazendonk HC; Lock J; Mathôt RA; Meijer K; Peters M; Laros-van Gorkom BA; van der Meer FJ; Driessens MH; Leebeek FW; Fijnvandraat K; Cnossen MH
    J Thromb Haemost; 2016 Mar; 14(3):468-78. PubMed ID: 26714028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5.
    Šaulytė Trakymienė S; Economou M; Kenet G; Landorph A; Shen C; Kearney S
    J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):15-25. PubMed ID: 32940955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial.
    Wu R; Sun J; Xu W; Hu Q; Li W; Xiao J; Yang F; Zeng X; Zeng Y; Zhou J; Matytsina I; Zhang S; Pluta M; Yang R
    Ther Clin Risk Manag; 2020; 16():567-578. PubMed ID: 32606716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.
    Agersø H; Stennicke HR; Pelzer H; Olsen EN; Merricks EP; Defriess NA; Nichols TC; Ezban M
    Haemophilia; 2012 Nov; 18(6):941-7. PubMed ID: 22812621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP.
    Pickering W; Hansen M; Kjalke M; Ezban M
    J Thromb Haemost; 2016 Aug; 14(8):1579-87. PubMed ID: 27241682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a tail vein transection bleeding model in fully anaesthetized haemophilia A mice - characterization of two novel FVIII molecules.
    Johansen PB; Tranholm M; Haaning J; Knudsen T
    Haemophilia; 2016 Jul; 22(4):625-31. PubMed ID: 26936336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.
    Stasyshyn O; Djambas Khayat C; Iosava G; Ong J; Abdul Karim F; Fischer K; Veldman A; Blackman N; St Ledger K; Pabinger I
    J Thromb Haemost; 2017 Apr; 15(4):636-644. PubMed ID: 28166608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).
    Manco-Johnson MJ; Kempton CL; Reding MT; Lissitchkov T; Goranov S; Gercheva L; Rusen L; Ghinea M; Uscatescu V; Rescia V; Hong W
    J Thromb Haemost; 2013 Jun; 11(6):1119-27. PubMed ID: 23528101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updates from guardian™: a comprehensive registration programme.
    Ozelo MC
    Eur J Haematol; 2015 Dec; 95 Suppl 81():22-9. PubMed ID: 26679394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A.
    Wu R; Wang X; Zhao X; Cheng Y; Zhou Z; Sun J; Xu M; Li W; Xiao J; Yang F; Chen Y; Xu W; Huang J; Ma C; Gai W; Xie L; Yang R
    Haemophilia; 2022 Nov; 28(6):e199-e208. PubMed ID: 35802040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A.
    Liu H; Wu R; Hu P; Sun F; Xu L; Liang Y; Nepal S; Qu PR; Huard F; Korth-Bradley JM
    Clin Ther; 2017 Jul; 39(7):1313-1319. PubMed ID: 28601434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and characterization of recombinant ovine coagulation factor VIII.
    Zakas PM; Gangadharan B; Almeida-Porada G; Porada CD; Spencer HT; Doering CB
    PLoS One; 2012; 7(11):e49481. PubMed ID: 23152911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor VIII therapy for hemophilia A: current and future issues.
    Aledort L; Ljung R; Mann K; Pipe S
    Expert Rev Hematol; 2014 Jun; 7(3):373-85. PubMed ID: 24717090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results.
    Tiede A; Klamroth R; Oldenburg J
    Hamostaseologie; 2015; 35(4):364-71. PubMed ID: 26271775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.